PharmacoEconomics and Outcomes News

EMEA announces results of paediatric drug use in Europe
pp. 1-1(1)

Russia: supply of essential medicines "beset by problems"
pp. 2-2(1)

Naftidrofuryl oxalate has been proposed as the recommended treatment for intermittent claudication in patients with peripheral arterial disease (PAD)
pp. 2-2(1)

NHS reforms radical
pp. 3-3(1)

Multichannel NHS takes on the information revolution
pp. 3-3(1)

USA's CDC updates its STD guidelines
pp. 4-4(1)

The UK's NICE has updated its guidelines on the use of aripiprazole [Abilify] to include patients aged 15−17 years with schizophrenia
pp. 4-4(1)

Autism guidelines could relieve "intense feeling of isolation" in UK
pp. 4-4(1)

NICE rules out antipsychotics for GAD and updates its guidelines
pp. 4-4(1)

Soaring costs of cardiovascular disease in the US
pp. 5-5(1)

Aripiprazole is the STAR for cost effectiveness in schizophrenia
pp. 5-5(1)

Bevacizumab a boon in bowel cancer
pp. 5-5(1)

A national increase in the use of home care services could save the USA billions, according to the Courtney C Brown Professor, Frank Lichtenberg
pp. 5-5(1)

News from ASH
pp. 6-7(2)

Rising off-label use of antipsychotics a concern in the US
pp. 7-7(1)

US cancer costs expected to grow by a massive 66% by 2020
pp. 7-7(1)

Triaging for colorectal cancer screening cost effective in UK . . .
pp. 8-8(1)

Outpatient management best approach for febrile neutropenia
pp. 8-8(1)

Study shows continued variation in use of NICE-approved drugs
pp. 9-9(1)

Over the counter Tamiflu "workable" in NZ
pp. 9-9(1)

Remote monitoring more cost effective than SOC in heart failure
pp. 9-9(1)

IL-2 and tretinoin more cost effective than bevacizumab
pp. 9-9(1)

Orlistat, paclitaxel + carboplatin & infliximab preferred by clinicians
pp. 10-10(1)

Is traditional cost-effectiveness analysis useful in terminal care?
pp. 10-10(1)

A generic formulation of ranitidine has been added to the National Drug Reimbursement List (NDRL) by China′s Ministry of Human Resources and Social Security.
pp. 10-10(1)

Quebec's Conseil du médicament has announced that denosumab [Prolia] will now be available to women with postmenopausal osteoporosis
pp. 10-10(1)

Savings of up to $490 million can be made on drug spending, says Hungary's minister for national economy, Gyorgy Matolcsy
pp. 11-11(1)

Degarelix [Firmagon] has been approved by the Scottish Medicines Consortium (SMC) for use in men with advanced hormone-dependent prostate cancer.
pp. 11-11(1)

Patients will be able to be treated (and be reimbursed) in another EU country as of 2013
pp. 11-11(1)

The UK government is increasing its aid donations to the Global Polio Eradication Initiative (GPEI) to £40 million this year and next year.
pp. 11-11(1)